Beyond Claims: The True Value of Lab Data in Prostate Cancer Therapy Commercialization
Prostate cancer (PC) remains a significant men's health concern, demanding innovative treatment...
Optimizing CLL Commercial Strategies with Lab Insights
Chronic Lymphocytic Leukemia (CLL) presents a complex treatment landscape. While advancements have...
Supporting HAE Commercial Teams with Prognos Health Lab Data
Hereditary angioedema (HAE) is a rare and debilitating condition affecting an estimated 1 in 50,000...
Illuminating Acromegaly: Lab Data Can Change HCP Engagement
Acromegaly, a rare hormonal disorder caused by excess growth hormone (GH) production, often goes...
Rapidly Identifying HCPs Treating AML: The Lab Data Advantage
Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow,...
Unlocking Precision Targeting in Lysosomal Storage Disorders: How Prognos Health Empowers Commercial Teams
Lysosomal Storage Disorders (LSDs) present a unique challenge for pharmaceutical and biotech...
Unveiling New Insights in NSCLC with Large-Scale FISH Panel Data
The landscape of Non-Small Cell Lung Cancer (NSCLC) treatment is constantly evolving, with...
How Emerging Biomarkers in Non-Small Cell Lung Cancer are Driving New and More Innovative Targeted Treatments
Lung cancer is one of the most common tumors and about 228,000 new cases will be diagnosed in the...
How Prognos is Using COVID-19 Data
Written by Jaclyn Fink, Data Quality Assurance Analyst, Prognos Health.
Factor This: Harnessing Lab-Testing Insights to Support Targeted Oncology Therapies in the Market
On World Cancer Day we recognize the countless brave people who have been affected by cancer and...